HER2-Positive Breast Cancer Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 10.81 Million |
| Market Size (2029) | USD 11.5 Million |
| CAGR (2024 - 2029) | 1.25 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
HER2-Positive Breast Cancer Treatment Market Analysis
The HER2-positive Breast Cancer Treatment Market size is estimated at USD 10.81 million in 2024, and is expected to reach USD 11.5 million by 2029, growing at a CAGR of 1.25% during the forecast period (2024-2029).
The market is driven by the rising incidence of HER2-positive breast cancer, growing awareness related to HER2-positive breast cancer, and product launches by market players.
The rapid rise of HER2-positive breast cancer cases and the increasing number of treatment options are among the significant factors driving the growth of the market studied. According to the August 2024 data published by the American Cancer Society, around 15% to 20% of breast tumors were caused by high levels of HER2 protein, causing HER2-positive breast cancer in the United States. Such factors are likely to boost the need for various treatment options to overcome HER2-positive breast cancer, thereby contributing to market growth.
In addition, according to a study published in NCBI in March 2022, HER2-positive breast cancer surged as the second most common type of cancer. The range of HER2+ was 2.6 per 100,000 women a decade ago, and it is projected to increase to 8.8 and 10.8 cases per 100,000 women by the year 2030. Thus, an increase in HER2-positive breast cancer is expected to increase demand for the treatment, contributing to market growth over the forecast period.
Moreover, the development of targeted drug treatment offers improved outcomes for patients. For instance, in August 2022, according to Breastcancer.ORG, target drug treatments such as monoclonal antibodies were made in the lab and worked similarly to antibodies made naturally by the body's immune system. These medicines target the HER2 receptors on breast cancer cells and help fight the cancer cells by alerting the immune system to destroy the cancer cells. Therefore, the development of new therapies to treat HER2-positive breast cancer is poised to accelerate the HER2-positive breast cancer treatment market and is expected to increase in the coming years, thereby driving the market's growth over the forecast period.
The approval of the treatment of HER2-positive metastatic breast cancer enabled targeted therapy for patients with lower levels of HER2 expression. This approval provided new treatment options for patients with HER2-low metastatic breast cancer, including those with HR-positive. This is expected to contribute to market growth. For instance, in July 2022, the European Union (EU) approved Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo, as a single-agent treatment for adults with unresectable or metastatic HER2-positive breast cancer. This approval is for patients who have previously received at least one anti-HER2-based therapy.
Therefore, the factors mentioned above, such as the high incidence of HER2-positive breast cancer, are anticipated to fuel market growth during the forecast period. However, the high cost of treatment is likely to impede market growth.
HER2-Positive Breast Cancer Treatment Market Trends
Chemotherapy Segment is Expected to Witness Growth Over the Forecast Period
Chemotherapy is a treatment that uses drugs and powerful chemicals to kill the fast-growing cancer cells in the body. Chemotherapy is the most common treatment for cancer. Chemotherapy drugs are used alone or as a combination to treat cancer. Chemotherapy is the primary or sole treatment for cancer. Similarly, chemotherapy can also be used for shrinking a tumor so that other possible treatments can be carried out in the body.
Moreover, trastuzumab, in combination with chemotherapy, is approved for the treatment of HER2-positive breast cancer and is shown to reduce the mortality rate. Hence, owing to the advantages offered by chemotherapy, the adoption of this treatment is likely to increase among the target population, ultimately driving market growth.
Market players engaging in strategic activities, such as product launches, mergers, and acquisitions, are expected to contribute to segment growth over the forecast period. For instance, in November 2023, Chugai Pharmaceutical Co. Ltd introduced Phesgo, a combination of subcutaneous injection trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination). This offering serves as an antineoplastic agent and anti-HER2 humanized monoclonal antibody, specifically designed for treating HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer that has progressed following cancer chemotherapy and is not amenable to curative resection.
Therefore, the high efficacy of chemotherapy against HER2-positive breast cancer and the growth of product launches are expected to boost segment growth over the forecast period.
North America is Expected to Witness a Significant Growth Over the Forecast Period
North America is expected to hold a significant share of the market owing to factors such as the easy availability of advanced treatment options and increasing awareness related to the treatment of HER2-positive breast cancer in the region. An increase in the number of cancer cases in the United States is among the key factors that drive the growth of the market in North America.
The growing burden of HER2-positive breast cancer in the region is expected to increase demand for effective treatment, thereby boosting market growth. For instance, as of May 2024, the Breast Cancer Research Foundation diagnosed breast cancer as the leading cancer among women in the United States. Notably, HER2-positive breast cancer, constituting roughly 20% of all breast cancer diagnoses, is a significant subset (translating to 297,790 women and 2,800 men diagnosed in 2023). On the other hand, HER2-low breast cancers, characterized by diminished HER2 expression, make up a substantial 55% of all breast cancer instances. Thus, the increasing number of breast cancer cases, such as HER2-positive breast cancer, is expected to promote the growth of the market in North America.
The growth of the HER2-positive breast cancer treatment market in North America is propelled by key product launches, a high concentration of market players, and a strong manufacturer presence. For instance, in May 2022, AstraZeneca and Daiichi Sankyo approved Enhertu (trastuzumab deruxtecan) for treating only HER2-positive breast cancer in the United States. These continuous product launches in the region are anticipated to drive the growth of the market in the country.
Therefore, owing to the factors mentioned above, such as the high burden of HER2-positive breast cancer and product launches, the North American market is expected to grow.
HER2-Positive Breast Cancer Treatment Industry Overview
The HER2-positive breast cancer treatment market is semi-consolidated in nature due to the presence of several companies operating globally and regionally. Key companies are engaged in various strategic activities such as mergers, acquisitions, and partnerships to increase their market presence and product portfolio. Some key players are Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bayer AG, GSK PLC, and Viatris (Mylan Inc.).
HER2-Positive Breast Cancer Treatment Market Leaders
-
Pfizer Inc.
-
AstraZeneca
-
F. Hoffmann-La Roche Ltd
-
Merck & Co., Inc.
-
Bayer AG
*Disclaimer: Major Players sorted in no particular order
HER2-Positive Breast Cancer Treatment Market News
- April 2024: The US Food and Drug Administration approved Enhertu, a drug that AstraZeneca and Daiichi Sankyo developed for treating adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors. This approval was for patients who had already undergone prior systemic treatment and had no other suitable treatment options available.
- January 2024: BioNTech SE and Duality Biologics commenced a pivotal Phase 3 clinical trial to assess the effectiveness and safety of BNT323/DB-1303, a novel antibody-drug conjugate (ADC) targeting HER2, a protein found on the surface of cancer cells.
HER2-positive Breast Cancer Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumption and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rapid Rise of HER2-positive Breast Cancer Cases
4.2.2 Increasing Number of Treatment Options
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.2 Targeted Drug Therapy
5.1.3 Other Treatment Types
5.2 By End User
5.2.1 Hospitals
5.2.2 Specialty Centers
5.2.3 Homecare
5.2.4 Other End Users
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 AstraZeneca
6.1.3 DAIICHI SANKYO COMPANY LIMITED
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Merck & Co. Inc.
6.1.6 Bayer AG
6.1.7 GSK plc
6.1.8 Biocon
6.1.9 Viatris Inc.
6.1.10 Teva Pharmaceutical Industries Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
HER2-Positive Breast Cancer Treatment Industry Segmentation
As per the scope of the report, HER2 (human epidermal growth factor receptor 2) is a protein that promotes the quick growth of breast cancer cells. Similarly, Her2-positive is a condition in which breast cancer cells have higher levels of HER2 proteins than normal levels. Overall, HER2-positive breast cancer is a type of cancer that tests positive for a protein called HER2.
The HER2-positive breast cancer treatment is segmented by treatment type, end user, and geography. By treatment type, the market is segmented into chemotherapy, targeted drug therapy, and other treatment types. By end user, the market is segmented into hospitals, specialty centers, homecare, and other end users. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
| By Treatment Type | |
| Chemotherapy | |
| Targeted Drug Therapy | |
| Other Treatment Types |
| By End User | |
| Hospitals | |
| Specialty Centers | |
| Homecare | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
HER2-positive Breast Cancer Treatment Market Research Faqs
How big is the HER2-positive Breast Cancer Treatment Market?
The HER2-positive Breast Cancer Treatment Market size is expected to reach USD 10.81 million in 2024 and grow at a CAGR of 1.25% to reach USD 11.5 million by 2029.
What is the current HER2-positive Breast Cancer Treatment Market size?
In 2024, the HER2-positive Breast Cancer Treatment Market size is expected to reach USD 10.81 million.
Who are the key players in HER2-positive Breast Cancer Treatment Market?
Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Merck & Co., Inc. and Bayer AG are the major companies operating in the HER2-positive Breast Cancer Treatment Market.
Which is the fastest growing region in HER2-positive Breast Cancer Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in HER2-positive Breast Cancer Treatment Market?
In 2024, the North America accounts for the largest market share in HER2-positive Breast Cancer Treatment Market.
What years does this HER2-positive Breast Cancer Treatment Market cover, and what was the market size in 2023?
In 2023, the HER2-positive Breast Cancer Treatment Market size was estimated at USD 10.67 million. The report covers the HER2-positive Breast Cancer Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the HER2-positive Breast Cancer Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
HER2-positive Breast Cancer Treatment Industry Report
Statistics for the 2024 HER2-positive Breast Cancer Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. HER2-positive Breast Cancer Treatment analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
